West Pharmaceutical Services (WST) Expected to Announce Quarterly Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) is expected to be issuing its Q2 2026 results before the market opens on Thursday, July 23rd. Analysts expect the company to post earnings of $2.08 per share and revenue of $839.9790 million for the quarter. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 23, 2026 at 8:00 AM ET.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The firm had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.67 million. During the same quarter in the previous year, the business earned $1.45 EPS. The business’s revenue was up 21.0% on a year-over-year basis. On average, analysts expect West Pharmaceutical Services to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

West Pharmaceutical Services Stock Down 1.4%

WST stock opened at $353.10 on Tuesday. The stock has a market capitalization of $24.95 billion, a price-to-earnings ratio of 47.21, a price-to-earnings-growth ratio of 2.90 and a beta of 1.16. The company has a 50-day moving average of $333.33 and a two-hundred day moving average of $285.41. West Pharmaceutical Services has a 52-week low of $208.71 and a 52-week high of $367.66. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on WST. TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Citigroup reaffirmed a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Wolfe Research began coverage on West Pharmaceutical Services in a report on Monday, June 1st. They set an “outperform” rating and a $375.00 price target for the company. Morgan Stanley increased their price objective on West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Finally, KeyCorp raised their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a research note on Thursday, July 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $363.17.

Insider Transactions at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares of the company’s stock, valued at $5,135,905.60. This represents a 14.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at $457,920.41. This represents a 37.04% decrease in their position. The SEC filing for this sale provides additional information. 0.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of WST. Generation Investment Management LLP boosted its holdings in shares of West Pharmaceutical Services by 60.0% during the 4th quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier’s stock worth $429,733,000 after buying an additional 585,855 shares during the period. T. Rowe Price Investment Management Inc. boosted its holdings in shares of West Pharmaceutical Services by 67.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,174,962 shares of the medical instruments supplier’s stock worth $323,280,000 after acquiring an additional 473,547 shares during the period. Steadfast Capital Management LP acquired a new position in shares of West Pharmaceutical Services in the third quarter valued at approximately $123,667,000. AQR Capital Management LLC grew its position in shares of West Pharmaceutical Services by 420.1% in the third quarter. AQR Capital Management LLC now owns 545,879 shares of the medical instruments supplier’s stock valued at $142,949,000 after purchasing an additional 440,929 shares during the last quarter. Finally, Viking Global Investors LP bought a new position in shares of West Pharmaceutical Services during the fourth quarter worth approximately $81,174,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.